Bone Biopsy Market is predicted to reach USD 964.55 million at a CAGR of 5.25% during the forecast period

Market Research Future (MRFR) has published a cooked research report on the “Global Bone Biopsy Market” that contains information from 2022 to 2030. The bone biopsy market is expected to register a CAGR of 5.25% during the forecast period 2022-2030, to reach USD 964.55 million by 2030.

MRFR recognizes the following companies as the key players in the global bone biopsy market— Argon Medical (US), B. Braun Melsungen (Germany), Becton, Dickinson, and Company (US), Cardinal Health, Inc. (US), Mermaid Medical A / S (Denmark), Kimal PLC (UK), Stryker (US), Cook Group Incorporated (US), Remington Medical (Denmark), and Merit Medical Systems Inc. (US).

Market Highlights

The global bone biopsy market is anticipated to reach a market value of USD 964.55 million by 2030 at a 5.25% CAGR. A bone biopsy is a procedure in which a small bone sample is removed from the outer layers of bone for examination, unlike a bone marrow biopsy, which involves the innermost part of the bone. The bone biopsy sample retains the architecture of bone when seen using a histopathological examination slide. The growth of global bone biopsy is driven by the factors such as the increasing prevalence of bone cancers and the growing demand for minimally invasive procedures. However, stringent regulatory policies hamper the growth of the global market. On the other hand, improving healthcare infrastructure across emerging countries is expected to create lucrative growth opportunities for players operating in the global market of bone biopsy.

Segment Analysis

The global bone biopsy market is segmented into type, guided, end-user and region. The type segment is further segmented into needle biopsy and open biopsy. The guided segment is categorized into MRI-guided and CT-guided. The end user segment is further bifurcated into hospitals & clinics, surgical centers, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Bone Biopsy Market Research Report

Regional Analysis

The global bone biopsy market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.

North America accounted for the largest share of the global market. This is attributed to the increasing prevalence of bone disorders such as bone cancer, osteoporosis osteomyelitis, and others. According to the American Cancer Society, an estimated 3,910 new cases of primary cancer of the bones and joints are expected to be diagnosed in the US, with about 2,100 deaths reported as a result of the disease in 2022. Moreover, the presence of favorable reimbursement policies, well-developed healthcare infrastructure, and rapid adoption of advanced medical technologies in the region is further positively contributing to the regional market growth during the forecast period.

Asia-Pacific is anticipated to register the highest growth rate over the forecast period. This is due to the factors such as improving healthcare infrastructure, government initiatives, and the increasing patient population suffering from bone cancer, bone Infection, osteoporosis, chronic kidney disease, and other bone disorders. For instance, according to the International Osteoporosis Foundation, by 2050, it is anticipated that Asia would account for over 50% of all osteoporotic hip fractures worldwide. Hence, the rise in bone disorders such as osteoporosis and bone cancer are anticipated to drive the market growth in the region as bone biopsy is used to confirm the diagnosis of a bone disorder, investigate an abnormality, determine the cause of pain or infection, and distinguish bone tumor from other conditions.

Key Findings of the Study

• The global bone biopsy market is estimated to reach USD 55 million by 2030 at a CAGR of 5.25% during the assessment period of 2022 to 2030.


• North America is expected to hold the largest share in the global market. The presence of major market players in the region such as Becton, Dickinson and Company (US), Cook Group Incorporated (US) & General Electric Company (US), strategic acquisitions to enhance product portfolio, and increasing prevalence of bone disorders such as bone cancer, osteoporosis osteomyelitis, and others are the key factors that contributed to the largest share.


• Based on type, the needle biopsy segment accounted for the largest market share of 68.11% in 2021.


• By guided, the CT-guided segment held the largest share of 57.73% and the MRI-guided segment is projected to be the fastest-growing segment during the forecast period.


• By end user, the hospitals and clinics segment held the largest share of 47.70%, and surgical centers is anticipated to be the fastest-growing segment during the forecast period.


• Some key players operating in the bone biopsy market are Argon Medical (US), B. Braun Melsungen (Germany), Becton, Dickinson, and Company (US), Cardinal Health, Inc. (US), Mermaid Medical A / S (Denmark), Kimal PLC (UK), Stryker (US), Cook Group Incorporated (US), Remington Medical (Denmark), and Merit Medical Systems Inc. (US).